Animal Model Core

项目摘要 我们的U19计划专注于B的病理生理学研究。炭疽感染和败血症， 潜在的新疗法。动物核心将作为U19计划的一个组成部分， 支持所有三个项目使用临床相关的败血症动物模型。调查人员将有一个 独特的机会，通过结合遗传多样性，临床相关的动物来回答关键问题 模型，该模型具有模拟人类对脓毒症的反应的历史， 在我们的项目中开发。 动物中心结合了一套独特的设施，管理和技术专长， 该计划的具体目标，以及专家兽医护理，专业试剂工具和强大的 在先进的生物化学和组织样本的显微镜分析的专业知识。涉事人员 Core在非人灵长类动物传染病建模方面拥有三十多年的经验。 最佳利用临床相关动物模型研究生物恐怖主义相关病原体，如B。 炭疽病需要一个设施，其中动物被安置在适当的生物遏制，研究人员 在传染病研究所需的方法学方面经验丰富，并开发了新的 需要治疗。我们的动物中心将使用最先进的设施来开发动物模型用于研究 疾病的发病机制和测试新疗法的有效性和安全性。我们的设施完全支持 ABSL-2的生物危害研究，并符合所有NIH/CDC指南。 因此，该核心是支持旨在开发创新疗法的提案的关键组成部分 对抗B。炭疽，我们相信这将与其他革兰氏阳性病原体有关。

Project Summary Our U19 program is focused on the investigation of the pathophysiology of B. anthracis infection and sepsis and potential novel therapies. The Animal Core will serve as an integral component of the U19 program, providing support to all three projects using a clinically relevant animal model of sepsis. The investigators will have a unique opportunity to answer critical questions by combining a genetically diverse, clinically relevant animal model, which has a proven history of mimicking human responses to sepsis with novel technologies being developed within our program. The Animal Core combines a unique set of facilities, management and technical expertise needed to achieve the Specific Aims of this program, as well as expert veterinary care, specialized reagent tools and strong expertise in advanced biochemical and microscopical analysis of tissue samples. The personnel involved in the Core have more than three decades of experience in infectious disease modeling in non-human primates. Optimal utilization of clinically relevant animal models for research on bioterrorism related pathogens such as B. anthracis requires a facility where animals are housed in appropriate biocontainment, research personnel are experienced in the methodologies required for infectious disease research, and development of novel therapeutics is required. Our Animal Core will use state-of-the-art facilities to develop animal models for studying disease pathogenesis and testing the efficacy and safety of novel therapeutics. Our facilities fully support biohazard research at ABSL-2 and meet all the NIH/CDC guidelines. Hence, this Core is a critical component in support of the proposals aimed at developing innovative therapeutics against B. anthracis, which we believe will be relevant to other Gram-positive pathogens.